PN
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Leveraging multi-organ models for drug combination therapy safety | Biomedicine & pharmacotherapy |  | 2025 | 9 | 29 | ||
| Microflow Liquid Chromatography Coupled to Multinozzle Electrospray Ionization for Improved Lipidomics Coverage of 3D Clear Cell Renal Cell Carcinoma | Analytical chemistry |  | 2025 | 29 | 1 | ||
| A cellular danse macabre: the choreography of programmed cell death | Apoptosis | | 2025 | 27 | 0 | ||
| Liposomal Tubacin: Strategies for the Formulation of a Highly Hydrophobic Anticancer Drug | Pharmaceutics | | 2025 | 34 | 115 | ||
| Preclinical Photodynamic Therapy Targeting Blood Vessels withAGuIX® Theranostic Nanoparticles | Cancers, 2024 | | 2024 | 31 | 23 | ||
| Generation and maintenance of kidney and kidney cancer organoids from patient-derived material for drug development and precision oncology | Molecular therapy. Methods & clinical development | | 2024 | 58 | 39 | ||
| Challenges in validation of combination treatment strategies for CRC using patient-derived organoids | Journal of experimental & clinical cancer research | | 2024 | 31 | 56 | ||
| New melphalan derivatives for the treatment of retinoblastoma in combination with thermotherapy | RSC medicinal chemistry | | 2024 | 24 | 43 | ||
| Nanoparticles Dysregulate the Human Placental Secretome with Consequences on Angiogenesis and Vascularization | Advanced science | | 2024 | 26 | 98 | ||
| Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer | Cellular and molecular life sciences | | 2023 | 122 | 224 | ||
| Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer | Oncoimmunology | | 2023 | 232 | 82 | ||
| Advanced in vitro models for renal cell carcinoma therapy design | Biochimica et biophysica acta, CR. Reviews on cancer | | 2023 | 91 | 197 | ||
| Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma | Journal of experimental & clinical cancer research | | 2023 | 176 | 69 | ||
| Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy | Nature communications | | 2022 | 180 | 101 | ||
| Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy | Angiogenesis | | 2022 | 190 | 71 | ||
| FOLFOXIRI Resistance Induction and Characterization in Human Colorectal Cancer Cells | Cancers | | 2022 | 251 | 120 | ||
| Characterization of Renal Cell Carcinoma Heterotypic 3D Co-Cultures with Immune Cell Subsets | Cancers | | 2021 | 166 | 209 | ||
| Drug repurposing to identify a synergistic high-order drug combination to treat sunitinib-resistant renal cell carcinoma | Cancers | | 2021 | 247 | 259 | ||
| A quarter century of Apoptosis | Apoptosis | | 2021 | 218 | 1 | ||
| COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects | Angiogenesis | | 2021 | 155 | 1 | ||
| Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes | Nature reviews. Clinical oncology | | 2021 | 401 | 5 | ||
| Molecular and Functional Analysis of Sunitinib-Resistance Induction in Human Renal Cell Carcinoma Cells | International journal of molecular sciences | | 2021 | 200 | 215 | ||
| Forcing dividing cancer cells to die; low-dose drug combinations to prevent spindle pole clustering | Apoptosis | | 2021 | 214 | 113 | ||
| Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) | European Journal of Heart Failure | | 2020 | 232 | 240 | ||
| Optimized low‐dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment | Molecular Oncology | | 2020 | 439 | 183 | ||
| Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma | British Journal of Cancer | | 2020 | 339 | 183 | ||
| Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment | Cancers | | 2020 | 247 | 123 | ||
| Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance | Cancers | | 2020 | 372 | 190 | ||
| Optimization for multidrug combinations: Challenges and perspectives in complex disorders | Pharmacological Research | | 2020 | 387 | 4 | ||
| Drug-Drug Interactions of Irinotecan, 5-Fluorouracil, Folinic Acid and Oxaliplatin and Its Activity in Colorectal Carcinoma Treatment | Molecules | | 2020 | 380 | 253 | ||
| Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma | Cancers | | 2020 | 342 | 259 | ||
| Programmed death, cells on the last train to glory | Apoptosis | | 2020 | 221 | 1 | ||
| Anti-angiogenic effects of crenolanib are mediated by mitotic modulation independently of PDGFR expression | British Journal of Cancer | | 2019 | 455 | 197 | ||
| Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer | Biochimica et Biophysica Acta. Reviews on Cancer | | 2019 | 488 | 702 | ||
| Oncofoetal insulin receptor isoform A marks the tumour endothelium; an underestimated pathway during tumour angiogenesis and angiostatic treatment | British Journal of Cancer | | 2019 | 325 | 151 | ||
| Identification of a Synergistic Multi-Drug Combination Active in Cancer Cells via the Prevention of Spindle Pole Clustering | Cancers | | 2019 | 539 | 304 | ||
| Colorectal Cancer Growth Retardation through Induction of Apoptosis, Using an Optimized Synergistic Cocktail of Axitinib, Erlotinib, and Dasatinib | Cancers | | 2019 | 289 | 102 | ||
| Short-term 3D culture systems of various complexity for treatment optimization of colorectal carcinoma | Scientific Reports | | 2019 | 444 | 260 | ||
| An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature | Vaccine | | 2018 | 319 | 236 | ||
| Targeting PDGF-mediated recruitment of pericytes blocks vascular mimicry and tumor growth | The Journal of Pathology | | 2018 | 259 | 151 | ||
| Apoptosis on the move | Apoptosis | | 2018 | 241 | 107 | ||
| IGF2 and IGF1R identified as novel tip cell genes in primary microvascular endothelial cell monolayers | Angiogenesis | | 2018 | 263 | 178 | ||
| Consensus guidelines for the use and interpretation of angiogenesis assays | Angiogenesis | | 2018 | 834 | 1,015 | ||
| Development of an Efficient Dual-Action GST-Inhibiting Anticancer Platinum(IV) Prodrug | ChemMedChem | | 2018 | 385 | 310 | ||
| Apoptosis turns 21 | Apoptosis | | 2017 | 214 | 110 | ||
| Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment | Angiogenesis | | 2017 | 298 | 386 | ||
| Angiogenesis inhibitors in combinatorial approaches | Angiogenesis | | 2017 | 234 | 0 | ||
| Beyond mouse cancer models: Three-dimensional human-relevant in vitro and non-mammalian in vivo models for photodynamic therapy | Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis | | 2017 | 206 | 0 | ||
| A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7) | Angiogenesis | | 2017 | 279 | 128 | ||
| Current Trends in Multidrug Optimization: An Alley of Future Successful Treatment of Complex Disorders | SLAS technology | | 2017 | 244 | 5 | ||
| miRNAs: micro-managers of anticancer combination therapies | Angiogenesis | | 2017 | 224 | 0 | ||
| Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link | Biological Reviews | | 2017 | 251 | 213 | ||
| Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity | Scientific Reports | | 2017 | 288 | 180 |
